Biology subjects

Saini, M.

Publications and source records attributed to Saini, M..

22 records · Page 2Linked to original sources

bioRxiv2020

Maintenance of epithelial traits and resistance to mesenchymal reprogramming promote proliferation in metastatic breast cancer

Despite important advances in the treatment of breast cancer, the 5-year survival rate for patients with distant metastasis remains less than 30%. Metastasis is a complex, multi-step process beginning with local invasion and ending with the outgrowth of systemically disseminated cells into actively proliferating metastases that ultimately cause the destruction of vital organs. It is this last step that limits patient survival and, at the same time, remains the least understood mechanistically. Here, we focus on understanding determinants of metastatic outgrowth using metastatic effusion biopsies from stage IV breast cancer patients. By modelling metastatic outgrowth through xenograft transplantation, we show that tumour initiation potential of patient-derived metastatic breast cancer cells across breast cancer subtypes is strongly linked to high levels of EPCAM expression. Breast cancer cells with high EPCAM levels are highly plastic and, upon induction of epithelial-mesenchymal transition (EMT), readily adopt mesenchymal traits while maintaining epithelial identity. In contrast, low EPCAM levels are caused by the irreversible reprogramming to a mesenchymal state with concomitant suppression of metastatic outgrowth. The ability of breast cancer cells to retain epithelial traits is tied to a global epigenetic program that limits the actions of EMT-transcription factor ZEB1, a suppressor of epithelial genes. Our results provide direct evidence that maintenance of epithelial identity is required for metastatic outgrowth while concomitant expression of mesenchymal markers enables plasticity. In contrast, loss of epithelial traits is characteristic of an irreversible mesenchymal reprogramming associated to a deficiency for metastatic outgrowth. Collectively, our data provide a framework for the intricate intercalation of mesenchymal and epithelial traits in metastatic growth.

cancer biology↗

bioRxiv2019

Plasmodium falciparum growth is regulated by Sphingosine 1 phosphate produced by Host Erythrocyte Membrane Sphingosine kinase 1

Sphingosine-1-phosphate (S1P) a bioactive lipid is produced in its primary reservoir, erythrocytes by an enzyme Sphingosine kinase-1 (SphK-1). The activation of such kinases and the subsequent S1P generation and secretion in the blood serum represent a major regulator of many cellular signaling cascades. Orthologue of sphingosine kinases 1 and 2 (SphK-1 and 2) that catalyze the phosphorylation of sphingosine generating S1P are not present in malaria parasite. The malaria parasite, Plasmodium falciparum, is an intracellular obligatory organism that reside in the human erythrocyte during its blood stage life cycle and orchestrates many metabolic interactions with host for its survival. Given the regulatory role of S1P, we targeted host SphK-1 by a generic pharmacological inhibitor N,N-Dimethyl-sphingosine (DMS) and analyzed growth of intra-erythrocytic parasite. We found that reducing S1P levels by inhibiting host SphK-1 activity led to halted parasite growth and ultimately cell death. Reduced intracellular S1P levels were attributed to decreased glycolysis marked by the low uptake of glucose by parasite and by less production of lactate, a byproduct of glycolysis. Reduced glycolysis was mediated by decrease translocation of the glycolytic enzyme, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to the cytosol of infected erythrocytes and cell death. Knocking down of erythrocyte SphK-1 is not lethal to the host and being a host encoded enzyme, targeting it with safe and specific drugs will not lead to the problem of resistance; thus, SphK-1 represents a potent target for the development of therapeutics against intra-erythrocytic P. falciparum.\n\nAuthor SummaryErythrocytes membrane enzyme Sphingosine kinase-1 (SphK-1) produces Sphingosine-1-phosphate (S1P) a bioactive lipid by phosphorylation of Sphingosine (Sph). S1P generated by activation of SphK is prosurvival signal and regulate cell growth. The malaria parasite, Plasmodium falciparum, is an intracellular obligatory pathogen that reside in erythrocyte during its blood stage life cycle and orchestrates many metabolic interactions with its host erythrocytes for survival. Orthologue of SphK-1/ 2 are not present in malaria parasite, therefore treatment with SphK inhibitor targeted host SphK-1 and led to reduced S1P level. The reduction in host S1P led to halted parasite growth and cell death. Furthermore, reduced erythrocyte S1P levels led to decreased glycolysis marked by the low uptake of glucose by parasite and by less production of lactate. Erythrocyte SphK-1 being a host encoded enzyme, is resistance safe and represents a potent target for the development of therapeutics against intra-erythrocytic P. falciparum.

cell biology↗

bioRxiv2019

High genetic diversity of Plasmodium falciparum in the low transmission setting of the Kingdom of Eswatini

ABSTRACTO_ST_ABSBackgroundC_ST_ABSTo better understand transmission dynamics, we characterized Plasmodium falciparum (Pf) genetic diversity in Eswatini, where transmission is low and sustained by importation.\n\nMethods26 Pf microsatellites were genotyped in 66% of all confirmed cases from 2014-2016 (n=582). Population and within-host diversity were used to characterize differences between imported and locally-acquired infections, as determined by travel history. Logistic regression was used to assess the added value of diversity metrics to classify imported and local infections beyond epidemiology data alone.\n\nResultsThe parasite population in Eswatini was highly diverse (HE=0.75) and complex, with 67% polyclonal infections, a mean MOI of 2.2, and mean FWS of 0.84. Imported cases had comparable diversity to local cases, but exhibited higher MOI (2.4 versus 2.0; p=0.004) and lower mean FWS (0.82 vs. 0.85; p=0.03). Addition of MOI and FWS to multivariate analyses did not increase discrimination between imported and local infections.\n\nDiscussionIn contrast to the commonly held perception that Pf diversity declines with decreasing transmission intensity, isolates from Eswatini exhibited high parasite diversity consistent with high rates of malaria importation and limited local transmission. Estimates of malaria transmission intensity from genetic data need to consider the effect of importation, especially as countries near elimination.

genetics↗

bioRxiv2018

Myosin Heavy Chain-embryonic is a crucial regulator of skeletal muscle development and differentiation.

Myosin heavy chains (MyHCs) are contractile proteins that are part of the thick filaments of the functional unit of the skeletal muscle, the sarcomere. In addition to MyHCs that are part of the adult muscle contractile network, two MyHCs - MyHC-embryonic and -perinatal are expressed during muscle development and are only transiently expressed in the adult during regeneration. The functions performed by these MyHCs has been a long-standing question and using a targeted mouse allele, we have characterized the role of MyHC-embryonic. Analysis of loss-of-function mice reveals that lack of MyHC-embryonic leads to mis-regulation of other MyHCs, alterations in fiber size, fiber number and fiber type at neonatal stages. We also find that loss of MyHC-embryonic leads to mis-regulation of genes involved in muscle differentiation. A broad theme from these studies is that loss of MyHC-embryonic has distinct effects on different muscles, possibly reflecting the unique fiber type composition of different muscles. Most significantly, our results indicate that MyHC-embryonic is required during embryonic and fetal myogenesis to regulate myogenic progenitor and myoblast differentiation in a non-cell autonomous manner via Mitogen Activated Protein Kinase (MAPKinase) and Fibroblast Growth Factor (FGF) signaling. Thus, our results signify that MyHC-embryonic is a key regulator of myogenic differentiation during embryonic, fetal and neonatal myogenesis.

developmental biology↗